The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Original Invest

6 Oct 2006 16:28

AIM06 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: ORIGINAL INVESTMENTS PLC (TO BE RENAMED VIALOGY PLC ON ADMISSION) COMPANY ADDRESS: ASHCOME COURTWOOLSACK WAYGODALMINGSURREY COMPANY POSTCODE: GU7 1LQ COUNTRY OF INCORPORATION: UK COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging their priorexpertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed a technology toseparate the background 'noise' that envelops weak signals called Quantum Resonance Interferometry (QRI), which has thepotential to be adapted to a wide range of measurement, instrumentation and other applications. The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able todetect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square) background noise. Thetechnology was the subject of further development work undertaken in the mass spectrometry industry. Other developmentactivities were carried out in the areas of sensor data processing and transference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be of considerablebenefit in a number of industrial areas and a planned programme of commercialisation has commenced. Discussions at bothdevelopment and commercial levels are being held with a number of international companies and national authorities toverify the suitability of incorporating the ViaLogy technology into existing and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 403,256,437 ORDINARY SHARES OF 1P EACH CAPITAL TO BE RAISED ON ADMISSION: NIL FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: DIRECTORS: JAMES DERRICK SLATER, CHAIRMAN (TO RESIGN ON ADMISSION) TERENCE BOND, MANAGING DIRECTOR AND DEPUTY CHAIRMAN (TO BECOME EXECUTIVE CHAIRMAN ON ADMISSION) DR RICHARD PETER DIXEY, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) JULIAN GEORGE VIGGARS, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) PROPOSED DIRECTORS: MICHAEL WOODS KELLY, PROPOSED CHIEF EXECUTIVE OFFICER DR. SANDEEP GULATI, PROPOSED CHIEF TECHNICAL OFFICER GEORGE REHM, PROPOSED NON-EXECUTIVE DIRECTOR DR. ROBERT WILLIAM DEAN, PROPOSED NON-EXECUTIVE DIRECTOR PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Existing Following AdmissionDirector Number of Percentage of Number of Percentage of Ordinary Shares issued ordinary Ordinary Shares issued ordinary share capital (%) share capital (%) James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5Christopher Slater 12,585,000 4.0 12,585,000 3.1Atlas Capital S.A. 17,700,000 5.7 17,700,000 4.4Dr. John Broome 12,500,000 5.3 13,316,542 3.3Aeris Holdings AG Nil Nil 60,883,923 15.1 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: NONE ANTICIPATED ACCOUNTING REFERENCE DATE: 31 MARCH EXPECTED ADMISSION DATE: 30 OCTOBER 2006 NAME AND ADDRESS OF NOMINATED ADVISER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL NAME AND ADDRESS OF BROKER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL THE ADMISSION DOCUMENT CONTAINS FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES. DATE OF NOTIFICATION: 6 OCTOBER 2006 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.